# V1 Empirics Check — openai/gpt-5.1-codex-mini (Variant A)

**Model:** openai/gpt-5.1-codex-mini
**Variant:** A
**Date:** 2026-03-31T10:44:17.457897

---

**Idea Fidelity**  
The paper mostly adheres to the manifest. It examines the staggered kratom prohibitions (2014–2017) as natural experiments and employs CDC VSRR fatal overdose data, while recognizing synthetic opioids as the hypothesized substitution target and psychostimulants/cocaine as negative controls. The main identification strategy—Callaway and Sant’Anna with complementary TWFE and robustness checks, including wild-cluster bootstrap and event-style tests—is as promised. The only divergence is that the manuscript relies more heavily on the C–S estimator with Arkansas, Alabama, and Rhode Island, rather than fully integrating the two 2014 cohorts (Indiana, Wisconsin) into the causal estimates, which slightly weakens the claim of using all five bans, but this limitation is transparently acknowledged.

**Summary**  
This paper studies whether state-level kratom bans increased opioid overdose mortality between 2015 and 2025. Using a staggered DiD design and the CDC’s provisional overdose death counts, it finds no positive treatment effect: the Callaway–Sant’Anna ATT is small and statistically indistinguishable from zero, while TWFE estimates show uniformly negative coefficients across opioid and stimulant categories, suggesting confounding trends rather than substitution. The null result is interpreted as evidence against the substitution hypothesis and is defended via negative controls, event‐study checks, and alternative inference methods.

**Essential Points**

1. **Limited Pre-treatment Variation and Power in the C–S Estimation.**  
   Only three states (AR, AL, RI) have pre-treatment data compatible with Callaway–Sant’Anna, so the causal estimates hinge on a very small number of treated clusters and potentially limited variation in the treatment timing. This raises concerns about power and the credibility of the parallel trends assumption even after controlling for fixed effects. A more thorough presentation of the event-study estimates (including graphical pre-trends for each cohort) and formal diagnostics (e.g., placebo leads, balance of trends) is necessary to demonstrate that the parallel trends condition holds for these three states relative to the control group. Without that, the null could simply reflect lack of identification.

2. **Interpretation of the TWFE Drug-Type Estimates.**  
   The uniformly negative TWFE coefficients across opioid and stimulant categories are taken as evidence of confounding trends, not treatment effects. But the paper needs to show more rigorously that these negative estimates are not driven by post-treatment dynamics (e.g., general downward trends in mortality coinciding with bans) or endogenous policy timing. In particular, the paper should present cohort-specific event studies for all five treated states (even if some are always-treated) to rule out pre-trends, and consider placebo tests where “pseudo-bans” are assigned to control states. Otherwise, the argument that the TWFE estimates are uninformative remains speculative.

3. **Measurement and Interpretation of Outcome Data.**  
   The 12-month rolling window structure of the VSRR data both smooths treatment effects and induces serial correlation; it is unclear whether the log-count specification appropriately accounts for these features. In addition, exclusion of eight states with substantial suppression could introduce selection bias if those jurisdictions would have helped identify the effect. The paper should be clearer on how missingness is handled (e.g., are missing observations imputed, or is the sample balanced?) and whether the excluded states differ systematically in policy or overdose trends. Without this, the generalizability of the null remains uncertain.

**Suggestions**

1. **Strengthen Identification Diagnostics.**  
   - Provide cohort-specific event-study plots (with confidence intervals) for the three C–S states, ideally also including the always-treated (possibly via pooled pre-bans or placebo “release” dates) to show that trends diverge only at the time of the ban.  
   - Conduct placebo tests by assigning fictitious ban dates to control states (at least a subset) and re-estimate the ATT to demonstrate that the estimator does not find spurious effects in the absence of real policy changes.  
   - Report balance tables or pre-period trend comparisons between treated states and their neighbors/controls to show that the parallel trends precondition is plausible.

2. **Clarify the Handling of Suppressed Data.**  
   - Explain whether the eight excluded jurisdictions are missing entirely or only for certain drug categories, and how their omission affects the composition of the control group. A short table comparing overdose trends and demographics (population size, overdose rate) between included and excluded states would help assess whether exclusion biases the results.  
   - If suppression is mostly a problem for opioid subtypes (not total overdoses), consider using imputation techniques or aggregate measures that remain available, along with sensitivity checks to ensure that sample attrition does not drive the observed null.

3. **Improve the Treatment of Rolling Window Outcomes.**  
   - Acknowledge and model the autocorrelation induced by the 12-month ending structure more explicitly. For instance, subtracting the previous month’s rolling count from the current month’s count recovers a synthetic “month-specific” death count (albeit still smoothed) and could provide a more responsive outcome. Alternatively, estimate models on the first differences of the log counts to reduce persistence.  
   - Consider weighting observations to reflect population size when interpreting log-count changes, or—at minimum—present average treatment effects on levels (e.g., deaths per 100,000) to show that the null holds across metric choices.

4. **Expand Discussion of Alternative Mechanisms and Heterogeneity.**  
   - Provide more empirical evidence (even descriptive) on enforcement/stringency differences across the five ban states. For example, are there data on kratom seizures, arrests, or retail closures that would indicate whether bans actually reduced availability? If not, state clearly that the interpretation of a “null” may hinge on enforcement intensity, and discuss how future research could address this with more disaggregated data.  
   - Report heterogeneity analysis: do the effects differ between small (e.g., Rhode Island) versus larger (e.g., Alabama) ban states, or by pre-ban opioid burden? Even with few treated units, a simple comparison of pre/post average trends in each state can illuminate whether any ban states deviate from expected patterns.

5. **Contextualize the Null in Terms of Detectable Effects.**  
   - The manuscript notes that the C–S confidence interval rules out increases above roughly 21%. It would be helpful to translate this into absolute terms (e.g., how many additional deaths per year per ban state could still be hidden within the CI?) and to compare this with plausible substitution magnitudes from prior studies (or from survey evidence on kratom prevalence).  
   - Consider a power analysis or simulation exercise to show what magnitude of effect could be detected with this design, clarifying that while large substitution effects are unlikely, the design may not rule out modest increases.

6. **Clarify Negative Control Strategy.**  
   - The psychostimulant and cocaine outcomes serve as negative controls, yet they also have their own dynamics driven by policy or supply shocks (e.g., methamphetamine surges). The paper should explain why these categories are valid negative controls despite potential cross-policy spillovers, and perhaps include additional “placebo” controls that are policy-inert (e.g., non-drug-related causes).  
   - When interpreting the triple-difference result, mention that a negative estimate could still arise if bans affected overall reporting or medical examiner behavior; the triple-difference can be interpreted more clearly if one shows that the pre-ban ratio of opioid to stimulant deaths is stable.

7. **Make the Policy Implications More Nuanced.**  
   - The conclusion suggests that “regulating kratom quality rather than criminalizing its use” should be the policy focus. This is a strong recommendation based on a null finding. Temper the language by emphasizing that while this study finds no detectable mortality impact at the state level, it does not necessarily prove that bans are harmless, especially if enforcement is uneven or substitution occurs at the individual level.  
   - Mention that further evidence (e.g., from individual-level datasets or natural experiments in more recent policy changes like Kratom Consumer Protection Acts) is necessary before drawing firm policy prescriptions.

Overall, the paper tackles an important question with novel data and a thoughtful research design. Addressing the identification diagnostics, data limitations, and interpretation of null results will make the contribution substantially stronger and more convincing to readers.
